Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 2.72
TROV's Cash to Debt is ranked higher than
50% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. TROV: 2.72 )
Ranked among companies with meaningful Cash to Debt only.
TROV' s 10-Year Cash to Debt Range
Min: 1.83  Med: 9999.00 Max: No Debt
Current: 2.72
Equity to Asset 0.42
TROV's Equity to Asset is ranked lower than
77% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. TROV: 0.42 )
Ranked among companies with meaningful Equity to Asset only.
TROV' s 10-Year Equity to Asset Range
Min: -4.07  Med: 0.42 Max: 0.75
Current: 0.42
-4.07
0.75
F-Score: 3
Z-Score: 0.31
M-Score: 5.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -6894.12
TROV's Operating margin (%) is ranked lower than
97% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. TROV: -6894.12 )
Ranked among companies with meaningful Operating margin (%) only.
TROV' s 10-Year Operating margin (%) Range
Min: -5337.5  Med: -2022.18 Max: -1077.56
Current: -6894.12
-5337.5
-1077.56
Net-margin (%) -9485.12
TROV's Net-margin (%) is ranked lower than
98% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.06 vs. TROV: -9485.12 )
Ranked among companies with meaningful Net-margin (%) only.
TROV' s 10-Year Net-margin (%) Range
Min: -5116.07  Med: -2570.22 Max: -867.83
Current: -9485.12
-5116.07
-867.83
ROE (%) -172.09
TROV's ROE (%) is ranked lower than
88% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.27 vs. TROV: -172.09 )
Ranked among companies with meaningful ROE (%) only.
TROV' s 10-Year ROE (%) Range
Min: -104.97  Med: -102.41 Max: -99.84
Current: -172.09
-104.97
-99.84
ROA (%) -73.17
TROV's ROA (%) is ranked lower than
80% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.44 vs. TROV: -73.17 )
Ranked among companies with meaningful ROA (%) only.
TROV' s 10-Year ROA (%) Range
Min: -288.72  Med: -121.47 Max: -51.11
Current: -73.17
-288.72
-51.11
ROC (Joel Greenblatt) (%) -2638.16
TROV's ROC (Joel Greenblatt) (%) is ranked lower than
92% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. TROV: -2638.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TROV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -18982.61  Med: -5332.80 Max: -1694.78
Current: -2638.16
-18982.61
-1694.78
» TROV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

TROV Guru Trades in

TROV Guru Trades in

TROV Guru Trades in

Q2 2015

TROV Guru Trades in Q2 2015

Jim Simons 132,100 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with TROV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.84
TROV's P/B is ranked lower than
83% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. TROV: 7.84 )
Ranked among companies with meaningful P/B only.
TROV' s 10-Year P/B Range
Min: 3.26  Med: 7.96 Max: 69.3
Current: 7.84
3.26
69.3
P/S 417.17
TROV's P/S is ranked lower than
99% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. TROV: 417.17 )
Ranked among companies with meaningful P/S only.
TROV' s 10-Year P/S Range
Min: 80  Med: 355.00 Max: 1283
Current: 417.17
80
1283
Current Ratio 8.47
TROV's Current Ratio is ranked higher than
89% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. TROV: 8.47 )
Ranked among companies with meaningful Current Ratio only.
TROV' s 10-Year Current Ratio Range
Min: 0.46  Med: 8.47 Max: 20.57
Current: 8.47
0.46
20.57
Quick Ratio 8.47
TROV's Quick Ratio is ranked higher than
91% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. TROV: 8.47 )
Ranked among companies with meaningful Quick Ratio only.
TROV' s 10-Year Quick Ratio Range
Min: 0.46  Med: 8.47 Max: 20.57
Current: 8.47
0.46
20.57
Days Sales Outstanding 126.30
TROV's Days Sales Outstanding is ranked lower than
87% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. TROV: 126.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
TROV' s 10-Year Days Sales Outstanding Range
Min: 74.3  Med: 111.33 Max: 140.06
Current: 126.3
74.3
140.06

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.08
TROV's Price/Net Cash is ranked higher than
54% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.50 vs. TROV: 9.08 )
Ranked among companies with meaningful Price/Net Cash only.
TROV' s 10-Year Price/Net Cash Range
Min: 4.17  Med: 9.76 Max: 208.67
Current: 9.08
4.17
208.67
Price/Net Current Asset Value 8.67
TROV's Price/Net Current Asset Value is ranked lower than
55% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.66 vs. TROV: 8.67 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
TROV' s 10-Year Price/Net Current Asset Value Range
Min: 4.07  Med: 9.45 Max: 156.5
Current: 8.67
4.07
156.5
Price/Tangible Book 7.84
TROV's Price/Tangible Book is ranked lower than
75% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.24 vs. TROV: 7.84 )
Ranked among companies with meaningful Price/Tangible Book only.
TROV' s 10-Year Price/Tangible Book Range
Min: 3.8  Med: 8.41 Max: 62.6
Current: 7.84
3.8
62.6
Price/Median PS Value 1.61
TROV's Price/Median PS Value is ranked lower than
87% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. TROV: 1.61 )
Ranked among companies with meaningful Price/Median PS Value only.
TROV' s 10-Year Price/Median PS Value Range
Min: 0.31  Med: 1.01 Max: 2.86
Current: 1.61
0.31
2.86
Earnings Yield (Greenblatt) (%) -18.00
TROV's Earnings Yield (Greenblatt) (%) is ranked lower than
78% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. TROV: -18.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TROV' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -19.51  Med: 0.00 Max: 0
Current: -18
-19.51
0

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 2 11 50 103
EPS($) -0.96 -0.93 -0.50 0.25
EPS without NRI($) -0.96 -0.93 -0.50 0.25

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:XE7A.Germany,
TrovaGene Inc was incorporated in the State of Delaware on April 26, 2002 as Used Kar Parts, Inc. On July 2, 2004, the Company acquired Xenomics, a California corporation, which was developing and commercializing TrDNA technology. As part of the acquisition, its corporate name was changed to Xenomics, Inc. (Xenomics) The Company re-domesticated its state of incorporation from Florida to Delaware and its name was changed to Trovagene, Inc. It is a development stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. Its novel tests predominantly use transrenal DNA, or Tr-DNA, and transrenal RNA, or Tr-RNA. The Company is leveraging its proprietary urine-based molecular diagnostic technology for the detection of cell-free DNA and RNA originating from diseased cell death that can be isolated from urine and detected to improve disease management. These genetic materials are also collectively referred to as cell-free nucleic acids, which result when cells in the body die and release their DNA or RNA into the bloodstream. Its fundamental urine-based molecular diagnostic platform is protected by a intellectual property portfolio. The Company's developed intellectual property around cell-free nucleic acids in urine, the extraction of cell-free nucleic acids from urine, as well as novel assay designs, particularly its proprietary non-naturally occurring primers. As of February 28, 2014, its property portfolio consists of over 130 issued patents and over 47 pending patent applications. The Company faces direct competition in the area of transrenal cell-free DNA or RNA detection and analysis is precluded by its growing patent estate. Its competitors include medical diagnostic companies, of which have financial, technical, and marketing resources greater than its resources.
» More Articles for TROV

Headlines

Articles On GuruFocus.com
Why People Lose Money Investing And What You Can Do About It Jul 29 2015 

More From Other Websites
TROVAGENE, INC. Financials Aug 22 2015
TROVAGENE, INC. Files SEC form 8-K, Other Events Aug 18 2015
Trovagene to Present Clinical Data and Capabilities of Its Urine-Based Liquid Biopsy Platform at the... Aug 18 2015
Trovagene to Present Clinical Data and Capabilities of Its Urine-Based Liquid Biopsy Platform at the... Aug 18 2015
Coverage initiated on TrovaGene by Leerink Partners Aug 14 2015
Insiders Are Buying Up Shares Of Sothebys (BID), Summit Hotel Properties Inc (INN), and TrovaGene... Aug 13 2015
Psychemedics Corp. Earnings Q2*, 2015 Aug 12 2015
TrovaGene Q2 Loss Widens on Higher Expenses, Shares Fall - Analyst Blog Aug 11 2015
Edited Transcript of TROV earnings conference call or presentation 10-Aug-15 9:00pm GMT Aug 10 2015
Trovagene reports 2Q loss Aug 10 2015
Trovagene reports 2Q loss Aug 10 2015
Trovagene, Inc. Announces Second Quarter 2015 Financial Results Aug 10 2015
TROVAGENE, INC. Files SEC form 8-K, Results of Operations and Financial Condition Aug 10 2015
TROVAGENE, INC. Files SEC form 10-Q, Quarterly Report Aug 10 2015
Trovagene, Inc. Announces Second Quarter 2015 Financial Results Aug 10 2015
Q2 2015 Trovagene Inc Earnings Release - 4:00 pm ET Aug 10 2015
TrovaGene (TROV): What???s in Store this Earnings Season? - Analyst Blog Aug 07 2015
Bridger Management Inceases Its Stake In TrovaGene Inc. (TROV) Via Its SPO Jul 23 2015
Trovagene Schedules Release of Second Quarter 2015 Financial Results and Investor Conference Call Jul 23 2015
Trovagene Schedules Release of Second Quarter 2015 Financial Results and Investor Conference Call Jul 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK